BARDA Archives - EverGlade Consulting

BARDA

enzymatic debridement product

BARDAs Strategic Investment in Enzymatic Debridement Products

Leave a Comment / BARDA, Life Sciences / By

Advancing Burn Care Preparedness: BARDA’s Strategic Investment in Enzymatic Debridement Products In its ongoing mission to strengthen the nation’s biodefense and emergency response infrastructure, the Biomedical Advanced Research and Development Authority (BARDA), an office within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, has released a […]

BARDAs Strategic Investment in Enzymatic Debridement Products Read More »

Transparent ampules on a blue background

BARDA’s Call to Action Antibiotics for Treatment of Bacterial Pneumonia or Bloodstream Infections

Leave a Comment / All Posts, BARDA, Life Sciences / By

Combating Resistant Infections: BARDA’s Push for Advanced Antibiotics The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), has released a pre-solicitation notice aimed at identifying qualified vendors to support the late-stage development, procurement, and stockpiling of antibiotics for critical public health threats. Targeted programs include

BARDA’s Call to Action Antibiotics for Treatment of Bacterial Pneumonia or Bloodstream Infections Read More »

Vaccine Development

BARDA’s Call to Action on Marburg and Sudan Virus Vaccines

Leave a Comment / BARDA, Life Sciences / By

Preparing for the Next Biological Threat: BARDA’s Vaccine Initiative for MARV and SUDV The Biomedical Advanced Research and Development Authority (BARDA), operating under the U.S. Department of Health and Human Services (HHS), has issued a pre-solicitation notice signaling its intent to launch a major Request for Proposal (RFP) later this year. This effort, managed by

BARDA’s Call to Action on Marburg and Sudan Virus Vaccines Read More »

Vaccine Research

Strengthening National Preparedness: BARDA’s FY23 Modernized BAA

Leave a Comment / BARDA, Life Sciences / By

Strengthening National Preparedness: BARDA’s FY23 Modernized BAA BAA-23-100-SOL-00004 – Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) In response to today’s evolving public health landscape, the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS) within the Administration for Strategic

Strengthening National Preparedness: BARDA’s FY23 Modernized BAA Read More »

Rapid Response Test

BARDA’s DxR2 RPP: Scaling Biothreat Diagnostic Readiness

Leave a Comment / All Posts, BARDA, Life Sciences / By

In a continued effort to bolster national preparedness against emerging biological threats, the Biomedical Advanced Research and Development Authority (BARDA) has released the Phase 2 issue of the “Biothreat Diagnostic Rapid Response” Solicitation (RPP-25-06-DxR2) on May 29, 2025, under its Rapid Response Partnership Vehicle (RRPV). BARDA is seeking to address pressing gaps in diagnostic test

BARDA’s DxR2 RPP: Scaling Biothreat Diagnostic Readiness Read More »

The White House Initiatives

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety

Leave a Comment / All Posts, ARPA-H, BARDA, Life Sciences / By

Promoting Domestic Production of Critical Medicines The White House is pushing to see more state-of-the-art pharmaceutical manufacturing facilities within the United States to strengthen the supply of essential medicines. On May 5, 2025, the President signed an Executive Order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines.” The goal of this order is

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety Read More »

immunoassay IEID Lab Solicitation

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats

Leave a Comment / All Posts, BARDA, Life Sciences / By

Why It Matters The rise of highly pathogenic avian influenza (HPAI) strains like H5N1, their spread to livestock, and increasing zoonotic infections in the U.S. has underscored the need for rapid, accurate immune assay infrastructure. BARDA’s RRPV initiative calls for laboratories with existing capabilities to function as a central immunoassay laboratory and perform quality-assured immunoassays

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats Read More »

BARDA merge with ARPA-H

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures

Leave a Comment / All Posts, BARDA, Life Sciences / By

The U.S. Department of Health and Human Services (HHS) is undergoing one of the most significant structural transformations in its history. This realignment affects not only public health preparedness and biomedical innovation but also the broader operational framework, including funding mechanisms, programmatic leadership, and cross-agency coordination structures that supports millions of Americans across health care,

What the HHS Reorganization Means for BARDA, Contractors, and the Office of Healthy Futures Read More »

antiviral therapeutics against filoviruses

New Opportunities with DRIVe: ReBooT and RePAIR Amendments

Leave a Comment / All Posts, BARDA, Life Sciences / By

Amendment 034 – DRIVe EZ BAA_ReBooT_RePAIR New Opportunities with DRIVe: ReBooT and RePAIR Amendments The Biomedical Advanced Research and Development Authority’s (BARDA) Division of Research, Innovation & Ventures (DRIVe) has announced updates to its Easy Broad Agency Announcement (EZ-BAA) with Amendment #034. This amendment reopens and revises the ReBooT (AOI #22) program and pauses the

New Opportunities with DRIVe: ReBooT and RePAIR Amendments Read More »

PAHPA program funding

After the CR: Funding Opportunities and Gaps in Pandemic Preparedness

Leave a Comment / All Posts, BARDA, Life Sciences / By

Congress’s passage of a continuing resolution (CR) has averted a shutdown and provided temporary relief until late March. However, this short-term fix exposes significant gaps in public health and technology preparedness that demand immediate attention. As critical programs approach expiration and threats beyond the Pandemic and All-Hazards Preparedness Act (PAHPA) remain unresolved, lawmakers have a

After the CR: Funding Opportunities and Gaps in Pandemic Preparedness Read More »

drug-resistant bacterial infections

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens

Leave a Comment / All Posts, BARDA, Life Sciences / By

PBS+AMR+2025+SSN+-+Final The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice (SSN) to gather insights from antibiotic developers working on solutions for drug-resistant bacterial infections. This SSN is part of BARDA’s Antimicrobial Resistance (AMR) Project BioShield, which focuses on understanding the current antibiotic landscape and potentially facilitating future acquisitions to combat

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens Read More »

Marburg virus (MARV) and Sudan virus (SUDV) vaccines clinical trials

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines

Leave a Comment / All Posts, BARDA, Life Sciences / By

SSN_MARV__SUDV_Vaccines Purpose The Biomedical Advanced Research and Development Authority (BARDA), under the Administration for Strategic Preparedness and Response (ASPR) has issued a Sources Sought Notice (SSN). The subject of this SSN is Marburg virus (MARV) and Sudan virus (SUDV) vaccines in active or completed Phase 2 clinical trials. Insights on current and prospective MARV and

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines Read More »

Scroll to Top